Gap in regulating biotech drug copies prompts WHO to step in

LONDON (Reuters) - Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike - but uneven regulation has created a lopsided market.